Literature DB >> 11324469

Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells.

X W Zhang1, J F Jiang, B Xu.   

Abstract

AIM: To study the mechanism of differentiation-inducing action of 10-hydroxycamptothecin (HCPT) on human hepatoma Hep G2 cells.
METHODS: The proliferating cell nuclear antigen (PCNA) expression was studied by immunocytochemical staining method. The cell cycle distribution and the wild-type protein p53 expression were measured by flow cytometry. Telomerase activity was assayed with telomeric repeat amplification protocol (TRAP).
RESULTS: After treatment with HCPT at differentiation-inducing concentrations 5-20 micrograms.L-1 for 6 d, Hep G2 cells were mainly arrested at G2/M phase and the PCNA expression rate was lower than that of control cells. When Hep G2 cells grew in a medium containing HCPT 5 micrograms.L-1 for 6 d, the p53 expression level markedly increased in comparison with the control cells. The telomerase activity did not change in Hep G2 cells treated with HCPT 5-20 micrograms.L-1 for 8 d.
CONCLUSION: The differentiation-inducing effect of HCPT on Hep G2 cells is related with the cell cycle arrest at G2/M phase, down-regulation of PCNA and up-regulation of wild-type protein p53.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11324469

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  8 in total

1.  Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways.

Authors:  Xiong Min; Han Heng; Hua-Long Yu; Mao Dan; Chen Jie; Yun Zeng; He Ning; Zhi-Gang Liu; Zhi-Yong Wang; Wang Lin
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

2.  Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma.

Authors:  Yi Zhang; Wen-Jie Song; Fu-Qin Zhang; Wei-Hui Liu; Ke-Feng Dou
Journal:  Dig Dis Sci       Date:  2011-02-12       Impact factor: 3.199

3.  Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma.

Authors:  Zhi-Jian Yu; Jia-Wei Yu; Wei Cai; Hong-Xin Yuan; Xiao-Yan Li; Ye Yuan; Jian-Ping Chen; Xiao-Yin Wu; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

4.  Induced differentiation of hepatocellular carcinoma by natural products.

Authors:  Xiong-Zhi Wu; Guang-Ru Xie
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-06-18

5.  Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.

Authors:  Zuhua Chen; Zhentao Liu; Wenwen Huang; Zhongwu Li; Jianling Zou; Jingyuan Wang; Xiaoting Lin; Beifang Li; Dongshao Chen; Yanting Hu; Jiafu Ji; Jing Gao; Lin Shen
Journal:  J Transl Med       Date:  2017-12-13       Impact factor: 5.531

6.  Nanogels as target drug delivery systems in cancer therapy: A review of the last decade.

Authors:  Anthony A Attama; Petra O Nnamani; Ozioma B Onokala; Agatha A Ugwu; Adaeze L Onugwu
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

7.  The effect of hydroxycamptothecin and pingyangmycin on human squamous cell carcinoma of the tongue.

Authors:  Peng Chen; Bing Liu; Ming Hu
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

8.  Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression.

Authors:  Bojian Fei; Alfred L Chi; Yuan Weng
Journal:  World J Surg Oncol       Date:  2013-05-30       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.